Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy

被引：8
|
作者：
von Eyben, Finn Edler [1 ]
Kulkarni, Harshad R. [2 ]
Baum, Richard P. [2 ]
机构：
[1] Ctr Tobacco Control Res, Odense, Denmark
[2] Zentralklin Bad Berka, Theranost Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
来源：
THERANOSTICS | 2020年 / 10卷 / 11期
关键词：
prostate specific membrane antigen; (177)Lutetium [Lu-177]-PSMA radioligand therapy; prostatic neoplasms; restaging; overall survival;
D O I：
10.7150/thno.44568
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with Lu-177 PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.
引用
收藏
页码：4900 / 4902
页数：3
相关论文
共 50 条
  • [1] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [2] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [3] Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects
    Fuoco, Valentina
    Argiroffi, Giovanni
    Mazzaglia, Stefania
    Lorenzoni, Alice
    Guadalupi, Valentina
    Franza, Andrea
    Scalorbi, Federica
    Aliberti, Gianluca
    Chiesa, Carlo
    Procopio, Giuseppe
    Seregni, Ettore
    Maccauro, Marco
    TUMORI JOURNAL, 2022, 108 (04): : 315 - 325
  • [4] Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer
    Eiber, Matthias
    Heck, Matthias
    Tauber, Robert
    Rauscher, Isabel
    D'Alessandria, Calogero
    Maurer, Tobias
    Retz, Margitta
    Wester, Hans
    Schwaiger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] Treatment efficacy and safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer
    Langbein, T.
    Retz, M.
    D'Alessandria, C.
    Grigorascu, S.
    Hansen, K.
    Wester, H.
    Gschwend, J.
    Weber, W.
    Eiber, M.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S132 - S133
  • [6] High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Groener, D.
    Davis, K. H.
    Wichert, J.
    Stefanova, M.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S647 - S648
  • [7] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [8] Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Gafita, Andrei
    Wang, Hui
    Tauber, Robert
    D'Alessandria, Calogero
    Weber, Wolfgang A.
    Eiber, Matthias
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (10) : 2212 - 2213
  • [9] Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Dwivedi, Sada Nand
    Bal, Chandrasekhar
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) : 275 - 285
  • [10] Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer
    Andrei Gafita
    Hui Wang
    Robert Tauber
    Calogero D’Alessandria
    Wolfgang A. Weber
    Matthias Eiber
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 2212 - 2213
12345